التحليلات
ما ننشره، عشناه في تكليف فعلي.
قراءتنا الحالية للرعاية الصحية وعلوم الحياة ورأس المال في الخليج. لا مقالات اتجاهات، ولا أخبار مُعاد تسخينها، بل ما كنّا سنعطيه لعميل يعمل على القرار نفسه.
متتبّع التشريعات والصفقات في قطاع الرعاية الصحية بالإمارات كل أداة تشريعية غيّرت طريقة تسعير الصفقات، ومعها المصدر الأولي لكلٍّ منها. متاح بالعربية بالكامل.
التحليلات أدناه منشورة باللغة الإنجليزية، وعناوينها معروضة كما نُشرت. المتتبّع أعلاه هو ما هو متاح بالعربية اليوم.
أغسطس 2026Dubai's DHA Clinical Research Standards: Trial Revenue Has a Compliance Deadline of 1 January 2027What DHA/HRS/MERD/ST-02 does to Dubai clinical-trial sponsors, CROs, and hospitals — and why a deal closing before 1 January 2027 treats it as a covenant, not a breach.أغسطس 2026The UAE is approving new medicines before the rest of the world. That changes launch sequencing.What two EDE approvals in sixteen days do to filing sequence, UAE revenue timing, and the economics of distribution agreements signed when the UAE was a late-launch market.أغسطس 2026DoH Abu Dhabi's Tele-Mental Health Standard: A New Licence GateWhat Standard DoH/ST/SCTMHS/HQS/V1/2026 does to the market-entry and diligence line for any Abu Dhabi mental-health target with remote consultation revenue.أغسطس 2026Abu Dhabi's Mental-Health Capacity Doubling: Reading a Dated Demand Statement Against a New Licence GateWhat the 3 August 2026 DoH capacity statement means for a buyer of an Abu Dhabi mental-health platform, read against the licence, Malaffi and AAMEN barriers a target must already clear.أغسطس 2026DoH Abu Dhabi's DME Policy V2: Home Medical Equipment, RepricedWhat Policy/DME/HPS/V2/2026 does to DME distributors, home-health providers, and DoH-authorised payers in Abu Dhabi — and where the diligence lines move.أغسطس 2026UAE's Ministerial Decision 91 of 2026: transplant capacity is now a fundable expansionHow UAE Ministerial Decision No. 91 of 2026 and the Hayat programme numbers published alongside it reprice transplant capacity for hospital operators, transplant programmes, insurers and investors.أغسطس 2026CDSCO closes the Phase III global-trial shortcut: India-first approvals no longer skip the IND DivisionWhat CDSCO's 10 August 2026 circular on Phase III Global Clinical Trials with Indian subjects means for MNC sponsors, India-based biotech, and the biotech funds valuing India-first approvals.أغسطس 2026Dubai Resolution 49: Free Zones Are Inside DHA NowWhy operators who built in a Dubai free zone to sit outside DHA are now inside its perimeter, and what Resolution 49/2024 does to a licence in a sale.أغسطس 2026IRDAI's 2026 TPA Amendment: What It RepricesWhat the 30 July 2026 IRDAI TPA amendment does to the value and the control structure of an Indian third-party administrator.يوليو 2026UAE EDE's 3PL Model: Enter Pharma Distribution Without Your Own WarehouseWhat the EDE's 29 July 2026 3PL storage model does to the capex line, the deal thesis, and the entry sequence for anyone chasing a UAE pharmaceutical distribution licence.يوليو 2026Clinical AI in Abu Dhabi now needs a governance fileUnder the DoH Responsible AI Standard, every clinical AI tool a group deploys needs documented explainability, privacy controls, and accountability sign-off.يوليو 2026UAE Family Office: DIFC vs ADGM, Decided FirstHow high-net-worth families should structure a UAE family office and holding vehicles across DIFC and ADGM, and why the framework has to be settled before assets are transferred.يوليو 2026Diligence on a Hospital Group: What Moves PriceDiligence on a multi-site medical-center network or hospital group is a discipline in itself, and the findings that reprice a deal sit in payer concentration, denial rates, per-facility licence conditions, health-information connectivity, and the new UAE merger-control regime.يوليو 2026Clinical costing: can your ERP reconcile to the EMR?Abu Dhabi's patient-level clinical costing requirement exposes the ERP-to-EMR integration gap most mid-size hospital groups still carry.يوليو 2026Abu Dhabi's Advanced-Therapy Land GrabAbu Dhabi's wave of BIO 2026 advanced-therapy partnerships opens a positioning window for provider groups with research infrastructure to become trial sites and centres of excellence.يوليو 2026Abu Dhabi's AED 55bn PPP Pipeline: Position NowAbu Dhabi's AED 55 billion PPP pipeline opens a health-infrastructure opportunity that rewards sponsors who arrive with grounded feasibility and a bankable financial model.يوليو 2026Why Geopolitical Risk Is Now a GCC Board Agenda ItemHow Red Sea logistics, war-risk exclusions, and force majeure disputes moved geo-risk onto the GCC board agenda.يوليو 2026Entering UAE Healthcare: The Sequence That WorksWhy UAE healthcare entries fail on sequence rather than strategy, and the order that actually works.يوليو 2026UAE Healthcare M&A: What 2026 Buyers Pay ForThe gap between what sellers think drives a healthcare valuation and what 2026 buyers actually pay a premium for.يوليو 2026GCC Expansion: One Market Is Not SixWhy GCC expansion demands country-by-country entry across six markets, disciplined distributor due diligence, and a Saudi strategy that does not assume the UAE approach carries over.يوليو 2026Financing a Buy-and-Build Healthcare PlatformThe right mix of debt and equity for a scaling hospital or medical-center-group platform depends on its cash generation and its stage, and the GCC's 2026 capital markets now offer sukuk, private equity, and staged structures to match each one.يونيو 2026The 2027 Emiratisation Clock on Clinical RolesThe UAE's 2027 rule directing half of the 2% Emiratisation target to clinical roles turns Emiratisation into a workforce-planning problem your group should be solving through 2026.يونيو 2026What Earns a 10x Healthcare MultipleAmanat's completion of full ownership of Cambridge Health Group at an implied ~10.5x EBITDA on our own arithmetic shows that scale and margin quality, not top-line revenue, are what command the platform multiple.يونيو 2026UAE Pharma Manufacturing: A Nine-Stage BuildThe nine-stage path from feasibility to WHO or EU GMP certification for UAE pharmaceutical manufacturing, and why localisation incentives do not shorten the qualification clock.يونيو 2026The Runway Before a DFM or ADX ListingWhy the premium multiple on a DFM or ADX listing is earned in the 18-to-24-month readiness window, and what an 18-point readiness assessment tests before the transaction begins.يونيو 2026Force Majeure Will Not Save an Unwritten ClauseWhy force majeure protection depends on clause scope and notification discipline, and how sanctions exposure can crystallise on contracts signed long before a designation.يونيو 2026Dubai built a new licence line for longevity clinicsDubai's Law No. 17 of 2026 has been in force since 13 June. Article 7(a) prohibits the longevity Activity without an Authority permit across the Emirate, free zones and the DIFC included, with no grandfathering, while the permit conditions themselves have not issued.يونيو 2026A High Denial Rate Costs You MoreDenial rates of 12-22% against a managed benchmark below 5% are a bigger prize than pricing, and Avior runs revenue cycle as a discipline rather than a reaction.يونيو 2026EDE Drug Registration: There Is No Verification RouteHow UAE marketing authorisation actually works under the Emirates Drug Establishment: one standard eCTD route scaled by product class, a separate 90-working-day pricing clock, and no reliance pathway for products approved by the FDA or EMA.يونيو 2026Where the Missing Margin Points WentThe gap between a 4% margin and a 12-18% benchmark is built and lost in service-line economics, pricing and procurement, and Avior recovers it with tracked impact.مايو 2026DHA and DoH Licensing: Sequence Before LeaseWhy UAE healthcare facility licensing under DHA or DoH must run in strict sequence, and how a stage-two decision determines what happens at stage six.مايو 2026Three Emirates, Three Compliance Regimes, One CalendarA multi-site group across Dubai, Abu Dhabi and Sharjah now carries three renewal calendars, three connectivity mandates and three penalty schedules, and needs one unified compliance spine to govern them.مايو 2026Sharjah tightened its health rulebook: map your sitesSharjah's 2026 amendment adds administrative penalties across government, private and free-zone facilities and their professionals, so groups with Sharjah sites need a Sharjah-specific policy map and a per-clinician re-credentialing plan.مايو 2026Why Healthcare and Pharma M&A Is DifferentWhat separates a healthcare or pharma acquisition from generic M&A, and why the valuation runs longer.مايو 2026UAE Business Setup: Free Zone, Mainland or DIFCWhy the free zone, mainland and DIFC or ADGM decision must be modelled against Corporate Tax and banking at establishment, not treated as paperwork.مايو 2026Arada's Reem Deal Opens a New Exit RouteA property developer's AED 2 billion commitment to Reem Hospital signals that strategics chasing recurring revenue now sit alongside PE and sovereigns as credible buyers for scalable multi-site healthcare brands.أبريل 2026UAE Merger Control Hits Healthcare DealsThe UAE's new merger-control regime forces pre-closing clearance on many healthcare deals, so regulatory runway and UBO disclosure now belong in the deal timeline.فبراير 2026The End of UAE Pharma ExclusivityThe end of the exclusive-distributor model in the UAE is an M&A and re-contracting catalyst that favours distributors with cold-chain, hospital and tender infrastructure.نوفمبر 2025Dubai's claims rulebook now puts your permit at riskDubai's PD-05-2025 rebuilds the claim lifecycle around eClaimLink with hard SLAs and permit-level penalties, forcing hospital and medical-center groups to run revenue cycle natively rather than around the system.نوفمبر 2025Day-case DRG in Abu Dhabi: coding now sets marginAbu Dhabi's move to case-based DRG for day-case procedures shifts margin from fee-for-service billing to coding accuracy and resource control.
اشترك
النشرة التنظيمية للرعاية الصحية في الإمارات
ما الذي تغيّر، وما الذي يعيد تسعيره، والأداة التشريعية التي يجب قراءتها. كل ثلاثاء ثانٍ. النشرة تصدر باللغة الإنجليزية.
رسالة واحدة كل أسبوعين، ويمكنك إلغاء الاشتراك من أيٍّ منها.